Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC

被引：0
|
作者：
Borghaei, H. [1 ]
Langer, C. J. [2 ]
Gadgeel, S. [3 ]
Papadimitrakopoulou, V. A. [4 ]
Patnaik, A. [5 ]
Powell, S. F. [6 ]
Gentzler, R. D. [7 ]
Martins, R. G. [8 ]
Stevenson, J. P. [9 ]
Jalal, S. I. [10 ]
Panwalkar, A. [11 ]
Yang, J. C-H. [12 ]
Gubens, M. [13 ]
Sequist, L. [14 ]
Awad, M. M. [15 ]
Fiore, J. [16 ]
Saraf, S. [16 ]
Raftopoulos, H. [16 ]
Gandhi, L. [17 ]
机构：
[1] Fox Chase Canc Ctr, Hematol & Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Abramson Canc Ctr, Dept Med, Philadelphia, PA USA
[3] Karmanos Canc Inst, Thorac Oncol, Detroit, MI USA
[4] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Oncol, Houston, TX 77030 USA
[5] South Texas Accelerated Res Therapeut, Clin Res, San Antonio, TX USA
[6] Sanford Heath, Oncol, Sioux Falls, SD USA
[7] Univ Virginia, Hematol Oncol, Charlottesville, VA USA
[8] Univ Washington, Med, Seattle, WA 98195 USA
[9] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[10] Indiana Univ Sch Med, Internal Med, Indianapolis, IN 46202 USA
[11] Sanford Roger Maris Canc Ctr, Hematol Oncol, Fargo, ND USA
[12] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[13] Univ Calif San Francisco, Med Oncol, San Francisco, CA 94143 USA
[14] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA
[15] Dana Farber Canc Inst, Thorac Oncol, Boston, MA 02115 USA
[16] Merck & Co Inc, Clin Res, Kenilworth, NJ USA
[17] NYU Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA49
引用
收藏
页数：2
相关论文
共 50 条
  • [1] First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.
    Papadimitrakopoulou, Vassiliki
    Gadgeel, Shirish M.
    Borghaei, Hossein
    Gandhi, Leena
    Patnaik, Amita
    Powell, Steven Francis
    Gentzler, Ryan D.
    Martins, Renato G.
    Stevenson, James
    Jalal, Shadia Ibrahim
    Panwalkar, Amit W.
    Yang, James Chih-Hsin
    Gubens, Matthew A.
    Sequist, Lecia V.
    Awad, Mark M.
    Fiore, Joseph
    Ge, Joy Yang
    Raftopoulos, Harry
    Langer, Corey J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G
    Langer, C.
    Gaddgeel, S. M.
    Borghaei, H.
    Papadimitrakopoulou, V. A.
    Patnaik, A.
    Powell, S.
    Gentzler, R. D.
    Martins, R. G.
    Stevenson, J. P.
    Jalal, S. I.
    Panwalkar, A.
    Yang, J. C-H.
    Gubens, M. A.
    Sequist, L. V.
    Awad, M. M.
    Fiore, J. J.
    Ge, Y.
    Raftopoulos, H.
    Gandhi, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update
    Borghaei, H.
    Langer, C.
    Gadgeel, S.
    Papadimitrakopoulou, V.
    Patnaik, A.
    Powell, S.
    Gentzler, R.
    Martins, R.
    Stevenson, J.
    Jalal, S.
    Panwalkar, A.
    Yang, J. C.
    Gubens, M.
    Sequist, L.
    Awad, M.
    Fiore, J.
    Saraf, S.
    Raftopoulos, H.
    Gandhi, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1791 - S1791
  • [4] Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC
    Awad, Mark M.
    Gadgeel, Shirish M.
    Borghaei, Hossein
    Patnaik, Amita
    Yang, James Chih-Hsin
    Powell, Steven F.
    Gentzler, Ryan D.
    Martins, Renato G.
    Stevenson, James P.
    Altan, Mehmet
    Jalal, Shadia I.
    Panwalkar, Amit
    Gubens, Matthew
    Sequist, Lecia V.
    Saraf, Sanatan
    Zhao, Bin
    Piperdi, Bilal
    Langer, Corey J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : 162 - 168
  • [5] KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC
    Awad, M. M.
    Gadgeel, S. M.
    Borghaei, H.
    Patnaik, A.
    Yang, J. Chih-Hsin
    Powell, S. F.
    Gentzler, R. D.
    Martins, R. G.
    Stevenson, J. P.
    Altan, M.
    Jalal, S. I.
    Panwalkar, A.
    Gubens, M.
    Sequist, L. V.
    Saraf, S.
    Zhao, B.
    Piperdi, B.
    Langer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S8 - S8
  • [6] 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.
    Gentzler, Ryan D.
    Langer, Corey J.
    Borghaei, Hossein
    Gadgeel, Shirish M.
    Papadimitrakopoulou, Vassiliki
    Patnaik, Amita
    Powell, Steven Francis
    Martins, Renato G.
    Stevenson, James
    Jalal, Shadia Ibrahim
    Panwalkar, Amit W.
    Yang, James Chih-Hsin
    Gubens, Matthew A.
    Sequist, Lecia V.
    Awad, Mark M.
    Fiore, Joseph
    Saraf, Sanatan
    Keller, Steven M.
    Gandhi, Leena
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer
    Borghaei, Hossein
    Langer, Corey J.
    Gadgeel, Shirish
    Papadimitrakopoulou, Vassiliki A.
    Patnaik, Amita
    Powell, Steven F.
    Gentzler, Ryan D.
    Martins, Renato G.
    Stevenson, James P.
    Jalal, Shadia I.
    Panwalkar, Amit
    Yang, James Chih-Hsin
    Gubens, Matthew
    Sequist, Lecia V.
    Awad, Mark M.
    Fiore, Joseph
    Saraf, Sanatan
    Keller, Steven M.
    Gandhi, Leena
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (01) : 124 - 129
  • [8] Pembrolizumab plus Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non-Small Cell Lung Cancer: KEYNOTE-021 Cohort G
    Langer, Corey
    Gadgeel, Shirish
    Borghaei, Hossein
    Papadimitrakopoulou, Vassiliki
    Patnaik, Amita
    Powell, Steve
    Gentzler, Ryan
    Martins, Renato
    Stevenson, James
    Jalal, Shadia
    Panwalkar, Amit
    Yang, James Chih-Hsin
    Gubens, Matthew
    Sequist, Lecia
    Fiore, Joseph
    Ge, Joy
    Raftopoulos, Harry
    Gandhi, Leena
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S391 - S392
  • [9] Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study
    van Laethem, J-L.
    Borbath, I.
    Karwal, M.
    Verslype, C.
    Van Vlierberghe, H.
    Kardosh, A.
    Zagonel, V.
    Stal, P.
    Sarker, D.
    Palmer, D.
    Vogel, A.
    Edeline, J.
    Cattan, S.
    Kudo, M.
    Cheng, A-L.
    Ogasawara, S.
    Siegel, A. B.
    Chisamore, M.
    Wang, A.
    Zhu, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S819 - S819
  • [10] Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
    Balar, A.
    Bellmunt, J.
    O'Donnell, P. H.
    Castellano, D.
    Grivas, P.
    Vuky, J.
    Powles, T.
    Plimack, E. R.
    Hahn, N. M.
    de Wit, R.
    Pang, L.
    Savage, M. J.
    Perini, R.
    Keefe, S.
    Bajorin, D.
    ANNALS OF ONCOLOGY, 2016, 27
12345